Protocol # 038-00: A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 when Administered Concomitantly with Peginterferon alfa-2b and Rabavirin in Treatment Naive Subjects wi